Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Mereo BioPharma Group plc (NASDAQ: MREO)
MREO Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
34.20%
Analyst Rating:
BUY
Analyst Forecast (1yr):
400%
MREO Stock Analysis
MREO
PE Ratio:
MREO
PEG Ratio:
Not Available
MREO
Forward EPS Growth (12 month):
0.00%
MREO
PS Ratio:
106.7
MREO
PSG Ratio:
1.5
MREO
Forward Revenue Growth (12 month):
70.50%
MREO Articles
No data was found